International Journal of Hematology and Oncology
2023, Vol 33, Num 4 Page(s): 213-219
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |
Follow-up of Chronic HBV Infected Patients Planned Chemotherapy Due to Solid Organ Malignancy
H. Aytac ERDEM1, Husnu PULLUKCU2, Meltem TASBAKAN2, Oguz R. SIPAHI2, Sercan ULUSOY2, Ruchan SERTOZ3, Ruchan USLU4, Tansu YAMAZHAN2
1Suat Seren Chest Diseases and Thoracic Surgery Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Izmir, TURKEY
2Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Izmir, TURKEY
3Ege University Faculty of Medicine, Department of Microbiology and Clinical Microbiology, Izmir, TURKEY
4Ege University Faculty of Medicine, Department of Medical Oncology, Ege University, Izmir, TURKEY
Keywords: Chemotherapy; HBV Reactivation, Solid Cancer
The aim of this study was to screen the patients with solid organ malignancy for HBV (Hepatitis B virus) infection before the start ofchemotherapy and follow up in the oncology department of our setting. All cases admitted to oncology department for chemotherapywere screened prospectively for HBV infection and reactivation between March 2013-September 2014. A total of 225 patients wereincluded in the study and divided into 3 groups; Group I: having recovered past HBV infection: 43 patients (19.1%), Group II: isolatedAnti-HBcAg total positive: 20 patients (8.9%) and Group III: chronic HBV infection with 10 patients (4.4%). HBV reactivation developedin one (5.9%) of 17 patients in group II, and two (28.6%) of seven patients in group III while under lamivudine prophylaxis. Neitherhepatitis flare by HBV reactivation nor HBV-related death were observed in our study. In the moderate endemicity areas like Turkeyfor HBV infection, all patients must be screened for HBV before starting of chemotherapy.
H. Aytac ERDEM1, Husnu PULLUKCU2, Meltem TASBAKAN2, Oguz R. SIPAHI2, Sercan ULUSOY2, Ruchan SERTOZ3, Ruchan USLU4, Tansu YAMAZHAN2
1Suat Seren Chest Diseases and Thoracic Surgery Training Hospital, Department of Infectious Diseases and Clinical Microbiology, Izmir, TURKEY
2Ege University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Izmir, TURKEY
3Ege University Faculty of Medicine, Department of Microbiology and Clinical Microbiology, Izmir, TURKEY
4Ege University Faculty of Medicine, Department of Medical Oncology, Ege University, Izmir, TURKEY
Keywords: Chemotherapy; HBV Reactivation, Solid Cancer
The aim of this study was to screen the patients with solid organ malignancy for HBV (Hepatitis B virus) infection before the start ofchemotherapy and follow up in the oncology department of our setting. All cases admitted to oncology department for chemotherapywere screened prospectively for HBV infection and reactivation between March 2013-September 2014. A total of 225 patients wereincluded in the study and divided into 3 groups; Group I: having recovered past HBV infection: 43 patients (19.1%), Group II: isolatedAnti-HBcAg total positive: 20 patients (8.9%) and Group III: chronic HBV infection with 10 patients (4.4%). HBV reactivation developedin one (5.9%) of 17 patients in group II, and two (28.6%) of seven patients in group III while under lamivudine prophylaxis. Neitherhepatitis flare by HBV reactivation nor HBV-related death were observed in our study. In the moderate endemicity areas like Turkeyfor HBV infection, all patients must be screened for HBV before starting of chemotherapy.
| Back | Table of Contents | Turkish Abstract | PDF | Mail to Author | |